Pacer Advisors, Inc. Blueprint Medicines Corp Transaction History

Pacer Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $6,558 - $8,376	77 Added 16.63%	540 $58,000
Q1 2024 May 10, 2024	BUY	$73.17 - $99.79 $33,877 - $46,202	463 New	463 $43,000
Q2 2021 Jul 21, 2021	SELL	$82.78 - $101.0 $59,932 - $73,124	-724 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$90.71 - $108.28 $38,823 - $46,343	-428 Reduced 37.15%	724 $70,000
Q4 2020 Jan 20, 2021	SELL	$92.08 - $124.48 $32,228 - $43,568	-350 Reduced 23.3%	1,152 $129,000
Q3 2020 Oct 19, 2020	BUY	$66.45 - $92.7 $99,807 - $139,235	1,502 New	1,502 $139,000
Q4 2018 Feb 13, 2019	SELL	$45.57 - $74.26 $166,831 - $271,865	-3,661 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $215,669 - $286,729	3,661 New	3,661 $286,000
Q1 2018 May 14, 2018	SELL	$73.28 - $102.95 $73,280 - $102,950	-1,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $62,910 - $88,320	1,000	1,000 $75,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.65B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.